Laboratory Evaluation of Platelet Function

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 731-742

  Seegmiller, Adam ^a   Sarode, Ravindra ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PLATELET DERIVED GROWTH FACTOR; THROMBIN; THROMBOSPONDIN; THROMBOXANE A2; VON WILLEBRAND FACTOR;

BERNARD SOULIER DISEASE; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; FLOW CYTOMETRY; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; STORAGE POOL DISEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE STRUCTURE; THROMBOCYTOPATHY; VON WILLEBRAND DISEASE;

BLOOD PLATELETS; HUMANS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS;

EID: 34547111278     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.008     Document Type: Review

References (85)

1. Italiano J.E., and Harwig J.H. Megakaryocyte and platelet structure. In: Hoffman R., Benz E.J., Shattil S.J., et al. (Eds). Hematology: basic principles and practice. 4th edition (2005), Elsevier, Philadelphia 1872-1880
2. Jurk K., and Kehrel B.E. Platelets: physiology and biochemistry. Semin Thromb Hemost 31 (2005) 381-392
3. Rendu F., and Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 12 (2001) 261-273
4. Gibbins J.M. Platelet adhesion signaling and the regulation of thrombus formation. J Cell Sci 117 (2004) 3415-3425
5. Hartwig J.H. The platelet: form and function. Semin Hematol 43 (2006) S94-S100
6. Smith W.L., Marnett L.J., and DeWitt D.L. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49 (1991) 153-179
7. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 86 (2001) 222-232
8. Shattil S.J., Hoxie J.A., Cunningham M., et al. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 260 (1985) 11107-11114
9. Brass L.F. The molecular basis of platelet activation. In: Hoffman R., Benz E.J., Shattil S.J., et al. (Eds). Hematology: basic principles and practice. 4th edition (2005), Elsevier, Philadelphia 1899-1914
10. Savage B., Cattaneo M., and Ruggeri Z.M. Mechanisms of platelet aggregation. Curr Opin Hematol 8 (2001) 270-276
11. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 (2002) 1382-1389
12. Oliver J.A., Monroe D.M., Church F.C., et al. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 100 (2002) 539-546
13. Hoffman M.M., and Monroe D.M. Rethinking the coagulation cascade. Curr Hematol Rep 4 (2005) 391-396
14. Ryan D.H. Examination of the blood. In: Beutler E., Lichtman M.A., Coller B.S., et al. (Eds). Williams hematology. 6th edition (2001), McGraw-Hill, New York 9-16
15. Lawrence L.B., Yomtovian R.A., Dillman C., et al. Reliability of automated platelet counts: comparison with manual method and utility for prediction of clinical bleeding. Am J Hematol 48 (1995) 244-250
16. Vajpayee N., Graham S.S., and Bern S. Basic examination of blood and bone marrow. In: Hutchison R.E., and McPherson R.A. (Eds). Henry's clinical diagnosis and management by lab methods. 21st edition (2007), Saunders Elsevier, Philadelphia 457-483
17. Lombarts A.J., and de Kieviet W. Recognition and prevention of pseudothrombocytopenia and concomitant pseudoleukocytosis. Am J Clin Pathol 89 (1988) 634-639
18. Newhouse P., and Clark C. The variability of platelet aggregation. In: Triplett D.A. (Ed). Platelet function: laboratory evaluation and clinical application (1978), ASCP, Chicago 63-107
19. Clinical Laboratory Standards Institute (CLSI). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays; approved guideline-fourth edition. CLSI document H21-A4 (ISBN 1-56238-521-6). 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA: Clinical and Laboratory Standards Institute; 2003.
20. Ts'ao C.H., Lo R., and Raymond J. Critical importance of citrate-blood ratio in platelet aggregation studies. Am J Clin Pathol 65 (1976) 518-522
21. Zucker M.B. Platelet aggregation measured by the photometric method. Methods Enzymol 169 (1989) 117-133
22. Walker I.D. Blood collection and sample preparation: pre-analytical variation. In: Jespersen J., Bertina R.M., and Haverkate F. (Eds). Laboratory techniques in thrombosis: a manual, 2nd revised edition of ECAT assay procedures (1999), Kluwer, Dordrecht (The Netherlands) 21-28
23. Dyszkiewicz-Korpanty A., Quinton R., Yassine J., et al. The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation. J Thromb Haemost 2 (2004) 354-356
24. Rodgers R.P., and Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 16 (1990) 1-20
25. Miller J.L., and Rao A.K. Blood platelets and von Willebrand disease. In: Hutchison R.E., and McPherson R.A. (Eds). Henry's clinical diagnosis and management by lab methods. 21st edition (2007), Saunders Elsevier, Philadelphia 747-769
26. Lind S. The bleeding time does not predict surgical bleeding. Blood 77 (1991) 2547-2552
27. De Caterina R., Lanza M., Manca G., et al. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 84 (1994) 3363-3370
28. Stiles K.P., Hill C., LeBrun C.J., et al. The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol 14 (2001) 275-279
29. Lehman C.M., Blaylock R.C., Alexander D.P., et al. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 47 (2001) 1204-1211
30. Hayward C.P.M., Harrison P., Cattaneo M., et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorder and platelet function. J Thromb Haemost 4 (2006) 312-319
31. Buyukasik Y., Karakus S., Goker H., et al. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 13 (2002) 349-353
32. Harrison P., Robinson M., Liesner R., et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 24 (2002) 225-232
33. Kottke-Marchant K., Powers J.B., Brooks L., et al. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 5 (1999) 122-130
34. Madan M., Berkowitz S.D., Christie D.J., et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 141 (2001) 226-233
35. Favaloro E.J. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 32 (2006) 537-545
36. Quiroga T., Goycoolea M., Munoz B., et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2 (2004) 892-898
37. Philipp C.S., Miller C.H., Faiz A., et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Hemophilia 11 (2005) 497-503
38. Poulsen T.S., Kristensen S.R., Atar D., et al. A critical appraisal of the phenomenon of aspirin resistance. Cardiology 104 (2005) 83-91
39. Marshall P.W., Williams A.J., Dixon R.M., et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100. Br J Clin Pharmacol 44 (1997) 151-155
40. Mammen E.F., Comp P.C., Gosselin R., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 (1998) 195-202
41. Andersen K., Hurlen M., Arnesen H., et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
42. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
43. Alberts M.J., Bergman D.L., Molner E., et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
44. Roller R.E., Dorr A., Ulrich S., et al. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer (PFA-100). Blood Coagul Fibrinolysis 13 (2002) 277-281
45. Chakroun T., Gerotziafas G., Robert F., et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 124 (2004) 80-85
46. Mueller T., Haltmayer M., Poelz W., et al. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 37 (2003) 117-123
47. Geiger J., Teichmann L., Grossmann R., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 (2005) 957-965
48. Van der Planken M.G., Claeys M.J., Vertessen F.J., et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 111 (2003) 159-164
49. Raman S., and Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2 (2004) 2278-2279
50. Grau A.J., Reiners S., Lichy C., et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34 (2003) 849-854
51. Hezard N., Metz D., Nazeyrollas P., et al. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?. Thromb Res 108 (2002) 43-47
52. Kundu S.K., Heilmann E.J., Sio R., et al. Characterization of an in vitro platelet function analyzer-PFA-100. Clin Appl Thromb Hemost 2 (1996) 241-249
53. Harrison P., Robinson M.S., Mackie I.J., et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 10 (1999) 25-31
54. Born G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962) 927-929
55. O'Brien J.R. Platelet aggregation. Part II: some results of a new method. J Clin Pathol 15 (1962) 452-425
56. Rodgers G. Qualitative platelet disorders and von Willebrand disease. In: Kjeldsberg C.R. (Ed). Practical diagnosis of hematologic disorders. 4th edition (2006), ASCP Press, Chicago 327-344
57. Dyszkiewicz-Korpanty A.M., Frenkel E.P., and Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11 (2005) 25-35
58. Santos M.T., Valles J., Marcus J., et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 87 (1991) 571-580
59. Bouchard B.A., and Tracy P.B. Platelets, leukocytes, and coagulation. Curr Opin Hematol 8 (2001) 263-269
60. Rand M.L., Leung R., and Packham M.A. Platelet function assays. Transfus Apher Sci 28 (2003) 307-317
61. Lecchi A., Zighetti M.L., Lussana F., et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. J Thromb Haemost 3 Suppl 1 (2005) P0965
62. Cannon C.P., McCabe C.H., Borzak S., et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban in patients after acute coronary syndrome. Circulation 97 (1998) 340-349
63. Cardinal D.C., and Flower R.J. The electric aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 3 (1980) 135-158
64. Ingerman-Wojenski C.M., and Silver M.J. A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb Haemost 51 (1984) 154-156
65. Joseph R., Welch K.M.A., and D'Andrea G. Epinephrine does not induce platelet aggregation in citrated whole blood. Semin Thromb Hemost 45 (1987) 871-872
66. Rawal A., Sarode R., Curtis B.R., et al. Acquired Glanzmann's thrombasthenia as part of multiple-autoantibody syndrome in a pediatric heart transplant patient. J Pediatr 144 (2004) 672-674
67. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
68. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
69. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
70. Kronick P.L., and Jimenez S.A. Simultaneous aggregation and release from platelets monitored continuously in plasma. Thromb Res 9 (1976) 553-563
71. Greenberg J., Packham M.A., Cazenave J.P., et al. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 32 (1975) 476-484
72. Michelson A.D. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med 110 (1987) 346-354
73. Jennings L.K., Ashmun R.A., Wang W.C., et al. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. Blood 68 (1986) 173-179
74. Gordon N., Thom J., Cole C., et al. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 89 (1995) 117-123
75. Wall J.E., Buijs-Wilts M., Arnold J.T., et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89 (1995) 380-385
76. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 98 (1997) 648-656
77. Gobbi G., Mirandola P., Tazzari P.L., et al. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia. Cytometry B Clin Cytom 58 (2004) 32-38
78. Michelson A.D. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 35 (2006) 67-82
79. Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 31 (2005) 393-399
80. Craft R.M., Chavez J.J., Bresee S.J., et al. A novel modification of the thromboelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 143 (2004) 301-309
81. Steinbuhl S.R. The VerifyNow system. In: Michelson A.D. (Ed). Platelets. 2nd edition (2006), Academic Press/Elsevier, San Diego (CA) 509-518
82. Craft R.M., Chavez J.J., Snider C.C., et al. Comparison of modified thromboelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 145 (2005) 309-315
83. Varon D., and Savion N. Impact cone and plate(let) analyzer. In: Michelson A.D. (Ed). Platelets. 2nd edition (2006), Academic Press/Elsevier, San Diego (CA) 535-544
84. Schwartz U.R., Geiger J., Walter U., et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 82 (1999) 1145-1152
85. Michelson A.D., Frelinger A.L., and Furman M.I. Current options in platelet function testing. Am J Cardiol 98 Suppl (2006) 4N-10N